Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
30 participants
INTERVENTIONAL
2022-07-27
2024-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Device Study for the Treatment of Acne
NCT04695691
A Post Market Device Study for the Treatment of Acne
NCT06469398
Laser Treatment of Moderate to Severe Acne Vulgaris
NCT04466527
Laser Therapy Versus Narrow Band Ultraviolet B for the Treatment of Acne Vulgaris
NCT04254601
Laser-Mediated Photodynamic Therapy of Acne Vulgaris and Rosacea
NCT00483145
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1726nm Laser Treatment
1726nm Laser System
Subjects will receive 1726nm laser treatments on one side of the face
Sham Laser Treatment
Sham Laser System
Subjects will receive sham laser treatments on the other side of the face.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
1726nm Laser System
Subjects will receive 1726nm laser treatments on one side of the face
Sham Laser System
Subjects will receive sham laser treatments on the other side of the face.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Fitzpatrick Skin Type I-VI
* Has clinically diagnosed acne vulgaris of moderate to severe on each hemiface and inflammatory acne lesions as determined by the blinded trained investigator (or qualified designee) using the Investigator's Global Assessment Scale.
* Subject (and legally authorized representative/substitute decision maker if subject is incapable of providing informed consent) must be able to read, speak, and understand English and sign the Informed Consent Form.
* Willing to stop using topical acne medications on the face for 2 weeks prior to baseline and systemic acne medications for 1 month prior to baseline and for the duration of the study.
* Willing and able to adhere to the treatment and follow-up schedule and pre/post-treatment care instructions.
* Willing to have very limited sun exposure (including avoiding tanning booths, sun lamps, sunbathing) and use an approved sunblock or sunscreen of SPF (Skin Protection Factor) 30 or higher on the face every day for the duration of the study, including the follow-up period.
* Willing to have photographs taken of the face and agree to the use of photographs for presentation, educational or marketing purposes.
* Agree to not undergo any other procedure(s) or add any new treatment modalities in the target area during the study.
Exclusion Criteria
* Prior treatment to the target area during participation in a clinical trial of another device or drug within 1 month (30 days) prior to study participation.
* Prior treatment to the target area within 1 month of study participation including chemical peel, dermabrasion/microdermabrasion, microneedling, radiofrequency treatment, laser or light-based procedures, cryodestruction or chemodestruction, intralesional steroids, photodynamic therapy, or acne surgery.
* Prior injection of botulinum toxin in the target area within 1 month of study participation and for the duration of the study.
* Prior injection of collagen, hyaluronic acid filler or other dermal/tissue filler in the target area within 2 weeks of study participation.
* Systemic use of retinoid, such as isotretinoin, within 6 months of study participation.
* Started or changed hormonal contraception within 6 months of study participation or intends to start or change hormonal contraception through duration of the study. If subject has not changed hormonal contraception within 6 months of study participation and has intent of continuation through duration of this study, ok to enroll.
* History of malignant tumors in the target area.
* Excessive facial hair (e.g., beards, sideburns, moustaches, etc.) or facial adornments (studs, piercings, tattoos) that may preclude treatments, photos or accurate lesion assessments in the target area.
* Pregnant and/or breastfeeding or planning to become pregnant during the study.
* Presence of any skin condition in the target area (e.g., eczema, psoriasis, dermatitis, rash, papulo-pustular rosacea, infection) that would interfere with the diagnosis or assessment of acne vulgaris.
* Any medical condition that, in the opinion of the Investigator, would interfere with patient's participation in the full study protocol (e.g., severe Diabetes Mellitus or Cardiovascular Disease).
* Suffering from diagnosed coagulation disorders or taking prescription anticoagulation medications.
* History of diagnosed immunosuppression/immune deficiency disorders or currently using immunosuppressive medications.
* History of diagnosed connective tissue disease, such as systemic lupus erythematosus or scleroderma.
* Known hypersensitivity to, history of allergic reaction to, or contraindication to Pro-Nox (or similar) if administered.
* Any use of medication that is known to increase sensitivity to light according to Investigator's discretion.
* History of disease stimulated by heat, such as recurrent herpes simplex and/or herpes zoster (shingles) in the target area, unless treatment is conducted following a prophylactic regimen.
* History of radiation to the target area, currently undergoing treatment for skin cancer in the target area or undergoing systemic chemotherapy for the treatment of cancer.
* History of diagnosed pigmentary disorders (including vitiligo) in the target area.
* Facial tan or unable/unlikely to refrain from tanning on the face during the study.
* As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.
16 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ethica Clinical Research Inc.
INDUSTRY
Cutera Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Canadian Dermatology Centre
Toronto, Ontario, Canada
Windsor Clinical Research
Windsor, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Michelle Mooney
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C-22-AC04
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.